Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(33.3%)

Phase 3

3(33.3%)

Phase 2

2(22.2%)

Phase 4

1(11.1%)

9Total

Phase 1(3)

Phase 3(3)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02631512Phase 4Completed

Evaluation of Woulgan in Diabetic Foot Ulcer

Role: lead

NCT00790322Phase 3Completed

Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy

Role: lead

NCT00533364Phase 1Completed

Effect of SBG in Patients With Breast Cancer

Role: lead

NCT00804414Phase 3Completed

Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers

Role: lead

NCT00632008Phase 3Completed

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

Role: lead

NCT00533728Phase 1Completed

Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma

Role: lead

NCT00283426Phase 1Terminated

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

Role: lead

NCT00289003Phase 2Completed

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Role: lead

NCT00288392Phase 2Completed

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

Role: lead

All 9 trials loaded